MacroGenics Inc (MGNX) stock
MGNXNasdaqPharmaceutical PreparationsFiscal year ends December 31
$1.96−0.02 (-1.01%)
Close on Nov 20, 2026Market cap $124.85MP/E –Yield –
MacroGenics gross profit
Gross profit is revenue minus the direct cost of the goods and services sold.
MacroGenics's gross profit for the twelve months ending Dec 31, 2025 was $149.50M, up 0.3% year over year. For fiscal 2025 it was $149.50M, up 0.3% from the year before. The highest annual figure on record is $149.50M in fiscal 2025.
Annual gross profit
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $149.50M | +0.3% |
| FY2024 | Dec 31, 2024 | $149.12M | +156.5% |
| FY2023 | Dec 31, 2023 | $58.13M | -60.9% |
| FY2022 | Dec 31, 2022 | $148.59M | +98.7% |
| FY2021 | Dec 31, 2021 | $74.80M | -28.7% |
| FY2020 | Dec 31, 2020 | $104.88M | +63.4% |
| FY2019 | Dec 31, 2019 | $64.19M | – |
Quarterly gross profit
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q4 FY2025 | Dec 31, 2025 | $41.23M | +115.6% |
| Q3 FY2025 | Sep 30, 2025 | $72.84M | -34.1% |
| Q2 FY2025 | Jun 30, 2025 | $6.87M | -35.3% |
| Q1 FY2025 | Mar 31, 2025 | $13.19M | +49.3% |
| Q4 FY2024 | Dec 31, 2024 | $19.12M | +81.1% |
| Q3 FY2024 | Sep 30, 2024 | $110.54M | +972.0% |
| Q2 FY2024 | Jun 30, 2024 | $10.62M | -17.5% |
| Q1 FY2024 | Mar 31, 2024 | $8.83M | -63.8% |
| Q4 FY2023 | Dec 31, 2023 | $10.56M | -85.5% |
| Q3 FY2023 | Sep 30, 2023 | $10.31M | -73.4% |
| Q2 FY2023 | Jun 30, 2023 | $12.88M | -50.1% |
| Q1 FY2023 | Mar 31, 2023 | $24.38M | +120.6% |
| Q4 FY2022 | Dec 31, 2022 | $72.98M | +452.9% |
| Q3 FY2022 | Sep 30, 2022 | $38.73M | +176.7% |
| Q2 FY2022 | Jun 30, 2022 | $25.83M | -16.0% |
| Q1 FY2022 | Mar 31, 2022 | $11.05M | -34.5% |
| Q4 FY2021 | Dec 31, 2021 | $13.20M | -74.9% |
| Q3 FY2021 | Sep 30, 2021 | $14.00M | -23.3% |
| Q2 FY2021 | Jun 30, 2021 | $30.74M | +51.7% |
| Q1 FY2021 | Mar 31, 2021 | $16.86M | +23.3% |
| Q4 FY2020 | Dec 31, 2020 | $52.69M | – |
| Q3 FY2020 | Sep 30, 2020 | $18.25M | – |
| Q2 FY2020 | Jun 30, 2020 | $20.26M | – |
| Q1 FY2020 | Mar 31, 2020 | $13.68M | – |
See a number that looks wrong?